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Abstract
Low reproducibility rates within life science research undermine cumulative knowledge
production and contribute to both delays and costs of therapeutic drug development. An
analysis of past studies indicates that the cumulative (total) prevalence of irreproducible
preclinical research exceeds 50%, resulting in approximately US$28,000,000,000 (US
$28B)/year spent on preclinical research that is not reproducible—in the United States
alone. We outline a framework for solutions and a plan for long-term improvements in re-
producibility rates that will help to accelerate the discovery of life-saving therapies
and cures.
Introduction
Much has been written about the alarming number of preclinical studies that were later
found to be irreproducible [1,2]. Flawed preclinical studies create false hope for patients
waiting for lifesaving cures; moreover, they point to systemic and costly inefficiencies in the
way preclinical studies are designed, conducted, and reported. Because replication and cu-
mulative knowledge production are cornerstones of the scientific process, these widespread
accounts are scientifically troubling. Such concerns are further complicated by questions
about the effectiveness of the peer review process itself [3], as well as the rapid growth of
postpublication peer review (e.g., PubMed Commons, PubPeer), data sharing, and open ac-
cess publishing that accelerate the identification of irreproducible studies [4]. Indeed, there
are many different perspectives on the size of this problem, and published estimates of irre-
producibility range from 51% [5] to 89% [6] (Fig 1). Our primary goal here is not to pin-
point the exact irreproducibility rate, but rather to identify root causes of the problem,
estimate the direct costs of irreproducible research, and to develop a framework to address
the highest priorities. Based on examples from within life sciences, application of economic
theory, and reviewing lessons learned from other industries, we conclude that community-
developed best practices and standards must play a central role in improving reproducibility
going forward.
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Defining Reproducibility
Studies of reproducibility define the phenomenon in a number of ways [10]. For example,
some studies define reproducibility as the ability to replicate the same results demonstrated in
a particular study using precisely the same methods and materials [11]; others evaluate whether
the study’s methodology and results were presented in sufficient detail to allow replication or
reanalysis [8]. The definition of reproducibility may also vary depending upon whether a par-
ticular study is confirmatory (designed to test basic theories through rigorous study design and
analysis) or exploratory (primarily aimed at developing theories and frameworks for further
study) [12]. For this paper, we adopt an inclusive definition of irreproducibility that encom-
passes the existence and propagation of one or more errors, flaws, inadequacies, or omissions
(collectively referred to as errors) that prevent replication of results. Clearly, perfect reproduc-
ibility across all preclinical research is neither possible nor desirable. Attempting to achieve
total reproducibility would dramatically increase the cost of such studies and radically curb
their volume. Our assumption that current irreproducibility rates exceed a theoretically (and
perhaps indeterminable) optimal level is based on the tremendous gap between the conven-
tional 5% false positive rate (i.e., statistical significance level of 0.05) and the estimates reported
below and elsewhere (see S1 Text and Fig 1). Although the optimal statistical power of each
study will depend on its objectives, this large gap suggests that published preclinical study re-
sults are often less reliable than claimed. From an economic perspective, the system is highly
inefficient. While there are several root causes, one overarching source of inefficiency is the
continued emphasis on placing responsibility with the researcher—despite the fact that a sig-
nificant portion of the costs of irreproducibility are ultimately borne by downstream parties in
the translation of bench discoveries to bedside therapies [13].
Fig 1. Studies reporting the prevalence of irreproducibility. Source: Begley and Ellis [6], Prinz et al. [7], Vasilevsky [8], Hartshorne and Schachner [5],
and Glasziou et al. [9].
doi:10.1371/journal.pbio.1002165.g001
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Analysis of Four Categories of Irreproducibility
Many studies have concluded that the prevalence of irreproducible biomedical research is sub-
stantial [1]. The wide range of published estimates reflects the challenges of accurately quanti-
fying and subsequently addressing the problem. Multiple systemic causes contribute to
irreproducibility and many can ultimately be traced to an underlying lack of a standards and
best practices framework [13]. However, it is reasonable to state that cumulative errors in the
following broad categories—as well as underlying biases that could contribute to each problem
area [14] or even result in entire studies never being published or reported [15]—are the prima-
ry causes of irreproducibility [16]: (1) study design, (2) biological reagents and reference mate-
rials, (3) laboratory protocols, and (4) data analysis and reporting. Fig 2, S1 Text, S1 and S2
Datasets show the results of our analysis, which estimates the prevalence (low, high, and mid-
point estimates) of errors in each category and builds up to a cumulative (total) irreproducibili-
ty rate that exceeds 50%. Using a highly conservative probability bounds approach [17], we
estimate that the cumulative rate of preclinical irreproducibility lies between 18% (the maxi-
mum of the low estimates, assuming maximum overlap between categories), and 88.5% (the
sum of the high estimates, assuming minimal overlap). A natural point estimate of the cumula-
tive irreproducibility rate is the midpoint of the upper and lower bounds, or 53.3%.
Limitations of the Analysis
This analysis is subject to a number of important limitations, including (1) the small number
of studies we were able to identify that provide or support the determination of low, high, and
midpoint estimates of prevalence rates for one or more categories of irreproducibility; (2) the
lack of consistency as to how reproducibility and irreproducibility are defined across studies;
and (3) in some cases, extrapolating from a clinical environment to the preclinical setting when
no suitable preclinical studies were available. For these reasons, a rigorous meta-analysis or sys-
tematic review was also not feasible. To estimate a theoretically optimal baseline rate of irrepro-
ducibility, we would also need data on the financial and opportunity costs of irreproducibility
and how these costs (and benefits) vary within the population of preclinical studies. Nonethe-
less, even simple calculations of direct costs can show that irreproducible preclinical research is
a significant problem in terms of lost dollars and lost opportunities for scientific discovery.
Economic Impact of Irreproducibility
Extrapolating from 2012 data, an estimated US$114.8B in the United States [18] is spent annu-
ally on life sciences research, with the pharmaceutical industry being the largest funder at
61.8%, followed by the federal government (31.5%), nonprofits (3.8%), and academia (3.0%)
[20]. Of this amount, an estimated US$56.4B (49%) is spent on preclinical research, with gov-
ernment sources providing the majority of funding (roughly US$38B) [19]. Using a conserva-
tive cumulative irreproducibility rate of 50% means that approximately US$28B/year is spent
on research that cannot be replicated (see Fig 2 and S2 Dataset). Of course, uncertainty remains
about the precise magnitude of the direct economic costs—the conservative probability bounds
approach reported above suggest that these costs could plausibly be much smaller or much
larger than US$28B. Nevertheless, we believe a 50% irreproducibility rate, leading to direct
costs of approximately US$28B/year, provides a reasonable starting point for further debate.
To be clear, this does not imply that there was no return on that investment. As noted in a re-
cent paper by Stern et al. [21], even in cases of retracted publications due to scientific miscon-
duct, which is not a major source of irreproducibility [13,22], “it is conceivable that some of the
research resulting in a retracted article still provides useful information for other nonretracted
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studies.”However, it does suggest that, even under our relatively conservative assumptions, the
impact of the reproducibility problem is economically significant.
Irreproducibility also has downstream impacts in the drug development pipeline. Academic
research studies with potential clinical applications are typically replicated within the pharma-
ceutical industry before clinical studies are begun, with each study replication requiring between
3 and 24 months and between US$500,000 to US$2,000,000 investment [23]. While industry
will continue to replicate external studies for their own drug discovery process, a substantially
improved preclinical reproducibility rate would derisk or result in an increased hit rate on such
investments, both increasing the productivity of life science research and improving the speed
and efficiency of the therapeutic drug development processes. The annual value added to the re-
turn on investment from taxpayer dollars would be in the billions in the US alone.
The Role of Best Practices and Standards
Many key stakeholder groups are developing and piloting a range of solutions to help increase
reproducibility in preclinical research. For example, the National Institutes of Health (NIH)
have recently announced a list of Principles and Guidelines for Reporting Preclinical Research
[24], which over 100 journals have joined as cosignatories and that builds on previous recom-
mendations by Landis et al. [25] to improve methodological reporting of animal studies in
Fig 2. Estimated US preclinical research spend and categories of errors that contribute to irreproducibility.Note that the percentage value of error for
each category is the midpoint of the high and low prevalence estimates for that category divided (weighted) by the sum of all midpoint error rates (see S1
Dataset). Source: Chakma et al. [18] and the American Association for the Advancement of Science (AAAS) [19].
doi:10.1371/journal.pbio.1002165.g002
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grant applications and publications. Despite the emergence of a wide variety of reporting
guidelines to improve reporting of biomedical research methods and results, to date, compli-
ance levels and their impact to improve reproducibility have been disappointing [26]. Given
the size, scale, and complexity of the challenge of reproducibility in preclinical research, there
is no single magic bullet solution to the problem. However, one issue that has shown demon-
strable impact on similar challenges in other settings is the expanded development and adop-
tion of standards and best practices [13].
In the information and communication technology industries, several standard development
organizations have moved beyond simply defining technical interfaces to assume the role of a
governing body for critical pieces of shared infrastructure. The Internet is a prime example. The
evolution of the Web has been messy; constrained by patent claims, the financial benefit of con-
trolling standards, and confusion over the evolutionary model. However, two organizations, the
WorldWide Web Consortium (W3C) and the Internet Engineering Task Force (IETF) emerged
to developWeb standards and maintain its interoperability as a universal space. TheW3C is an
excellent example of a successful, internally driven and self-regulating international consortium
comprising a public and private partnership working together. Similarly, the IETF operates as a
noncommercial/not-for-profit/nongovernmental organization and operates a large number of
work groups and informal discussion groups, working on specific, timely issues, then disbanding
once these issues are addressed. In the early days of the Internet, both groups successfully steered
major global players toward common standards requiring each to compromise and adapt in the
short term, but ultimately gain tremendous benefits over the longer horizon.
Although neither example focuses directly on reproducibility, they highlight the importance
for the life sciences to engage all stakeholders in a dynamic, collaborative effort to standardize
common scientific processes. In the clinical research arena, where the stakes are high and over-
sight by the US Food and Drug Administration (FDA) is stringent, irreproducibility has been
reduced to rates that are generally considered to be scientifically and commercially appropriate
[1]. However, this level of stringent oversight often precludes the direct application of clinical
methods, practices, and procedures to preclinical research [27]. Furthermore, in a clinical set-
ting, the number of assays and interventions is tightly controlled, which is not typically possible
in a basic or preclinical research environment without incurring a significant increase in time
and cost. Nonetheless, economic research also has shown that standardization and auditing of
biological materials—through biological resource centers—can enhance cumulative production
of scientific knowledge by improving both availability and reliability of research inputs [28].
An illustrative example is the use and misuse of cancer cell lines. The history of cell lines
used in biomedical research is riddled with misidentification and cross-contamination events
[29], which have been estimated to range from 15% to 36% [30]. Yet despite the availability of
the short tandem repeat (STR) analysis as an accepted standard to authenticate cell lines, and
its relatively low cost (approximately US$200 per assay), only one-third of labs typically test
their cell lines for identity [31]. For an NIH-funded academic researcher receiving an average
US$450,000, four-year grant, purchasing cell lines from a reputable vendor (or validating their
own stock) and then authenticating annually will only cost about US$1,000 or 0.2% of the
award. A search of NIH Reporter for projects using “cell line” or “cell culture” suggests that
NIH currently funds about US$3.7B annually on research using cell lines. Given that a quarter
of these research projects apparently use misidentified or contaminated cell lines, reducing this
to even 10% through a broader application of the STR standard—a very realistic goal—would
ensure a more effective use of nearly three-quarters of a billion dollars and ultimately speed the
progress of research and the development of new treatments for disease.
The economics literature on standardization posits that unless there is a clearly dominant
platform leader willing to impose a solution, complex challenges such as irreproducibility that
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require a coordinated response are best solved by internally organized and driven, dynamic, and
self-regulating collaborations of key stakeholders who establish and enforce their respective rules
of engagement [32,33]. What is needed is not another list of unfunded mandates, but rather
community consensus on priorities for improvement and commitment for the additional fund-
ing for implementation. This includes training that focuses specifically on the importance of
standards and best practices in basic research in graduate and postdoctoral programs, as well as
quality management systems to ensure that best practices are implemented throughout the re-
search process. No doubt that improving training and increasing quality control measures will
add costs to the preclinical research enterprise. One estimate in a clinical setting suggests the
adoption of mandated quality control procedures would increase costs to 15% to 25% above cur-
rent spending levels [34]. However, the societal benefits garnered from an increase in reproduc-
ible life science research far outweigh the cost. Assuming that we could recover even half of the
approximately US$28 billion annually spent on irreproducible preclinical research in the US
alone by applying best practices and standards, the savings would be roughly US$14B/year.
Moreover, because our analysis indicates that errors in study design and biological reagents and
materials contribute to a majority of this spend (see Fig 2), implementing steps to improve pre-
clinical reproducibility should be a priority in these two areas (see Box 1).
Box 1. Investing in Practical Solutions
Taking immediate steps in two areas where there will be significant return on investment—
study design and biological reagents and reference materials—will yield substantial im-
provements in preclinical reproducibility rates.
Study Design
• Improve training programs at academic institutions to ensure that best practices are re-
inforced in the areas of core skills, methods, technology, and tools.
• Establish targeted training, coaching, and certification of established principal investi-
gators (PIs) to reinforce application of best practices throughout the research process.
• Establish research funder policies, including funders such as NIH and leading disease
foundations, requiring successful completion of training courses at all levels.
Biological Reagents and Reference Materials
• Promote broad adoption by vendors to offer only validated reagents (e.g., antibodies
and cell lines) and broad utilization of these reagents by PIs as a documented best prac-
tice in the research process.
• Ensure that research funder policies require documented use of validated and noncon-
taminated reagents, annual reagent authentication throughout the research study, and
adequate funding to cover these additional costs.
• Ensure that procedures to document reagent validation and lack of contamination are
required by publishers.
• Incentivize the continued development of tools for reagent validation using improved
genomics data.
• Define standard operating procedures for biological materials handling throughout the
material’s lifecycle.
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In order to change practices throughout the preclinical research community, all invested
stakeholders (academia, journals, industry, and government) must work in partnership to de-
velop, institutionalize, and reward (or even sanction) behaviors, working within a mutually
agreed upon set of rules and guiding principles. Such dynamic collaborations could more effi-
ciently represent the needs of all stakeholders and provide unifying guidance and funding sug-
gestions to facilitate meaningful change. Establishing effective collaborative efforts is no simple
feat, but we can look to other industries that have been successful in the past as models for the
life science community.
Conclusions
Although differing perspectives on the irreproducibility rate in preclinical research may persist,
one fact remains clear: the challenge of increasing reproducibility and addressing the costs as-
sociated with the lack of reproducibility in life science research is simply too important and
costly to ignore. Lifesaving therapies are being delayed, research budgets face increasing pres-
sure, and drug development and treatment costs are rising. Improving reproducibility remains
a critical cornerstone to solving each of these challenges. There are no easy answers to this
problem. Real solutions, such as addressing errors in study design and using high quality bio-
logical reagents and reference materials, will require time, resources, and collaboration between
diverse stakeholders that will be a key precursor to change. Millions of patients are waiting for
therapies and cures that must first survive preclinical challenges. Although any effort to im-
prove reproducibility levels will require a measured investment in capital and time, the long-
term benefits to society that are derived from increased scientific fidelity will greatly exceed the
upfront costs.
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